

## RITUXIMAB MEDICATION ORDER

**Patient's Name** (Last, First, Middle) \_\_\_\_\_ **DOB:** \_\_\_\_\_

■ **Diagnosis**

Diagnosis and the most specific ICD-10 code available: \_\_\_\_\_

■ **Details Needed for Authorization** *Other indications may require other documentation.*

Rheumatoid Arthritis

- If order is for Rituxan, does the patient have a failure, contraindication or allergy to Truxima or Ruxience? \_\_\_\_\_
- Has the patient been diagnosed with moderate-to-severe active RA? \_\_\_\_\_
- Is Rituximab being used in combination with methotrexate? \_\_\_\_\_ If not, is there a contraindication/intolerance? \_\_\_\_\_
- Has the patient tried and failed at least a 3 month trial of methotrexate, leflunomide, sulfasalazine and/or hydroxychloroquine? \_\_\_\_\_ If not, is there an intolerance or contraindication to all conventional agents? \_\_\_\_\_
- Has the patient tried another biological immunomodulator agent FDA labeled or compendia supported for RA? \_\_\_\_\_
- Has the patient been treated with Rituximab in the past 16 weeks? \_\_\_\_\_
- Please provide us with detailed notes on disease status, progression, activity, prognosis, past medications trialed, and full history.

Pemphigus Vulgaris

- If order is for Rituxan, does the patient have a failure, contraindication or allergy to Truxima or Ruxience? \_\_\_\_\_
- \_\_\_\_\_
- Has the patient been diagnosed with moderate-to-severe PV? \_\_\_\_\_
- Indicate all clinical signs exhibited:
  - Lesions/Erosions/Blisters       Nikolsky sign       Characteristic scarring and lesion distribution
- Include written report of Histopathologic confirmation by skin/mucous membrane biopsy.
- Include results demonstrating presence of autoantibodies as detected by direct or indirect immunofluorescence.
- Have you ruled out other causes of blistering or erosive skin and mucous membrane diseases? \_\_\_\_\_

■ **Premedication Order**

*Oral medications to be taken by the patient at least 60 minutes prior to start of infusion treatment. May be taken at home before coming in.:*

- Acetaminophen \_\_\_\_\_mg       Cetirizine \_\_\_\_\_mg       Diphenhydramine \_\_\_\_\_mg

*IV medications to be administered prior to start of the infusion treatment:*

- Dexamethasone \_\_\_\_\_mg       Famotidine \_\_\_\_\_mg       Methylprednisolone \_\_\_\_\_mg  
 Diphenhydramine \_\_\_\_\_mg       Metoclopramide \_\_\_\_\_mg       \_\_\_\_\_

■ **Rituximab Order**

- Rituxan                       Ruxience                       Truxima

DAW: Please check here to administer only as written. If not checked, we may substitute your brand of choice depending on availability / allocation. (If your brand choice is unavailable and this box is checked, a new order will be needed to change brands.)

# RITUXIMAB MEDICATION ORDER, CONTINUED ...

Patient's Name (Last, First, Middle) \_\_\_\_\_ DOB: \_\_\_\_\_

Dose: \_\_\_\_\_ mg/kg Patient's height in ft/in: \_\_\_\_\_ Patient's weight in lbs: \_\_\_\_\_

## Rate

- \_\_\_\_\_ ml over \_\_\_\_\_ minutes  
 Start at \_\_\_\_\_ ml/hr, after \_\_\_\_\_ minutes increase to \_\_\_\_\_ ml/hr, after \_\_\_\_\_ minutes increase to \_\_\_\_\_ ml/hr

## Volume

- \_\_\_\_\_ ml of normal saline  \_\_\_\_\_ ml of half normal saline  \_\_\_\_\_ ml of D5W

Frequency: To be administered every \_\_\_\_\_ for \_\_\_\_\_. (Ex: every 2 days for 3 weeks)

- If filtered tubing is required, indicate particle size filter to be used: 0.2 $\mu$  or 1.2 $\mu$

After the infusion is complete, flush with normal saline. Check vitals and monitor for signs and symptoms of an infusion reaction at start, throughout infusion, and after completion.

## ■ Rescue Management in case of Infusion Therapy Reaction

Stop medication infusion and start normal saline infusion at 50 ml/hr. Call ordering provider to report reaction. Follow standing reaction orders, including diphenhydramine, methylprednisolone, albuterol and oxygen as needed. For severe reactions, administer Epi-pen or equivalent and call 911. Repeat if severe symptoms persist.

## ■ Documentation to Include

- Patient demographics and insurance, including allergies and including card scans (both medical and pharmacy benefit cards, both sides).
- Most recent chart notes and, if available, last history and physical. All relevant scans, tests and laboratory results (including CBC with platelet, quantitative immunoglobulins, Hepatitis B antigen, Hepatitis B core total antibody and QuantiFERON gold).
- If this is a new medication for patient, chart notes which include decision to begin treatment. If the patient is already being treated on this therapy, provide last treatment date and notes.

## ■ Ordering Provider Authorization

Provider's Signature: \_\_\_\_\_ Name: \_\_\_\_\_ Date: \_\_\_\_\_

Address: \_\_\_\_\_

Phone: \_\_\_\_\_ Fax: \_\_\_\_\_ NPI #: \_\_\_\_\_ License: \_\_\_\_\_

**Fax this order and all supporting documentation to (732) 329-2322.**